{"id":"bdp-salbutamol-cfc-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Nervousness/anxiety"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beclomethasone dipropionate (BDP) is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors, reducing mucus production and airway edema. Salbutamol (albuterol) is a short-acting beta-2 adrenergic agonist that rapidly relaxes bronchial smooth muscle, providing acute bronchodilation. The CFC formulation uses chlorofluorocarbon propellants in a pressurized metered-dose inhaler (pMDI) for drug delivery.","oneSentence":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:46.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance and reliever therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"}]},"trialDetails":[{"nctId":"NCT00528723","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-11","conditions":"Bronchial Asthma","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clenil® Compositum 250"],"phase":"phase_3","status":"active","brandName":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}